ADAR1 Capital Management, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), ADAR1 Capital Management, LLC reported 185 stock positions worth $505.1 million. Its top holding was Protagonist Therapeutics (PTGX) at 9.0% of the portfolio, followed by Alpha Architect 1-3 MNTH Box (BOXX, 7.4%) and Roivant Sciences (ROIV, 7.0%). Compared with Q4 2024, it opened 44 new positions, sold out of 44, added to 68 and reduced 40. The biggest buy was Keros Therapeutics (KROS, shares +6294%) and the biggest sale Ascendis Pharma A/S (ASND, shares −98%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $505.1M (Q1 2025)
- SEC Filing
- 0001940272-25-000003 ↗ filed May 15, 2025
Holdings Value
Holdings 185 stocks · $505.1M
| PTGX Protagonist Therapeutics Inc. | 9.00% | 939,669 | $45.4M | Reduce -7.9% |
| BOXX Alpha Architect 1-3 MNTH Box | 7.44% | 337,125 | $37.6M | Add +3.6% |
| ROIV Roivant Sciences Ltd. | 6.96% | 3,483,404 | $35.1M | Reduce -0.7% |
| ZLAB Zai Lab Ltd.-ADR | 6.73% | 940,858 | $34.0M | Reduce -10.0% |
| IMVT Immunovant Inc. | 3.28% | 968,866 | $16.6M | Add +23.0% |
| CYTK Cytokinetics Inc. | 3.11% | 390,729 | $15.7M | Reduce -5.7% |
| KROS Keros Therapeutics Inc. | 3.00% | 1,486,461 | $15.1M | Add +6294.5% |
| ABVX Abivax SA-ADR | 2.73% | 2,210,019 | $13.8M | Add +46.0% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 2.46% | 135,585 | $12.4M | Add +2.9% |
| BBIO Bridgebio Pharma Inc. | 2.32% | 339,635 | $11.7M | Reduce -50.0% |
| IKT Inhibikase Therapeutics Inc. | 2.22% | 5,122,105 | $11.2M | Add +0.4% |
| SWTX Springworks Therapeutics Inc. | 1.82% | 207,778 | $9.2M | New |
| SHY iShares 1-3 Year Treasury Bo | 1.69% | 103,337 | $8.5M | New |
| TEVA Teva Pharmaceutical-SP ADR | 1.59% | 523,767 | $8.1M | Add +257.1% |
| SRPT Sarepta Therapeutics Inc. | 1.55% | 122,921 | $7.8M | Add +207.3% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 1.53% | 750,000 | $7.7M | No change |
| CGON CG Oncology Inc. | 1.46% | 301,134 | $7.4M | Add +39.6% |
| RAPT THERAPEUTICS INC | 1.44% | 5,970,768 | $7.3M | Add +408.4% |
| ABUS Arbutus Biopharma Corp. | 1.30% | 1,879,114 | $6.6M | Add +20.9% |
| ITCI Intra-Cellular Therapies Inc. | 1.25% | 48,044 | $6.3M | New |
| RVMD Revolution Medicines Inc. | 1.24% | 177,136 | $6.3M | Add +4.2% |
| AVR Anteris Technologies Global | 1.21% | 1,678,063 | $6.1M | Add +59.4% |
| AAM Aa Mission Acquisition Cor-A | 1.19% | 578,359 | $6.0M | Add +3.2% |
| SAGE Sage Therapeutics Inc. | 1.17% | 742,495 | $5.9M | Add +3767.2% |
| ETNB 89BIO Inc. | 1.16% | 804,220 | $5.8M | Add +56.1% |
| OACCU Oaktree Acquisition III Life | 1.07% | 516,482 | $5.4M | Add +3.3% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.05% | 469,729 | $5.3M | Add +16.2% |
| AMLX Amylyx Pharmaceuticals Inc. | 1.03% | 1,471,587 | $5.2M | New |
| SRRK Scholar Rock Holding Corp. | 1.00% | 157,079 | $5.1M | Add +705.3% |
| XENE Xenon Pharmaceuticals Inc. | 0.85% | 127,548 | $4.3M | Add +152.3% |
| XNCR Xencor Inc. | 0.84% | 398,152 | $4.2M | Add +69.7% |
| MLYS Mineralys Therapeutics Inc. | 0.83% | 263,425 | $4.2M | Reduce -68.7% |
| SEPN Septerna Inc. | 0.83% | 720,848 | $4.2M | New |
| JANX Janux Therapeutics Inc. | 0.82% | 153,767 | $4.2M | Add +388.0% |
| APGE Apogee Therapeutics Inc. | 0.78% | 104,853 | $3.9M | Add +154.0% |
| SVRA Savara Inc. | 0.75% | 1,360,291 | $3.8M | Add +37.6% |
| MNPR Monopar Therapeutics Inc. | 0.73% | 100,774 | $3.7M | Reduce -22.5% |
| AEROVATE THERAPEUTICS INC | 0.73% | 1,461,234 | $3.7M | Add +57.5% |
| BIOA Bioage Labs Inc. | 0.72% | 971,100 | $3.7M | Add +689.3% |
| ZURA Zura Bio Ltd. | 0.72% | 2,801,184 | $3.6M | Add +34.9% |
| ATXS Astria Therapeutics Inc. | 0.68% | 641,690 | $3.4M | Add +605.3% |
| RZLT Rezolute Inc. | 0.64% | 1,116,047 | $3.2M | Reduce -17.9% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.62% | 216,166 | $3.1M | Add +40.3% |
| AKRO Akero Therapeutics Inc. | 0.57% | 71,143 | $2.9M | Add +364.8% |
| MRUS Merus NV | 0.56% | 66,960 | $2.8M | Reduce -17.8% |
| PTCT PTC Therapeutics Inc. | 0.50% | 50,023 | $2.5M | Add +4.2% |
| RGNX Regenxbio Inc. | 0.50% | 350,352 | $2.5M | Add +105.9% |
| ARDX Ardelyx Inc. | 0.48% | 490,743 | $2.4M | Add +1481.3% |
| DVAX Dynavax Technologies Corp. | 0.44% | 170,000 | $2.2M | New |
| ARVN Arvinas Inc. | 0.44% | 313,354 | $2.2M | New |
| ASPC A Spac III Acquisition Class A | 0.43% | 215,000 | $2.2M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 0.39% | 36,890 | $2.0M | Add +19.2% |
| DCTH Delcath Systems Inc. | 0.38% | 149,385 | $1.9M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 0.35% | 53,125 | $1.8M | No change |
| KALA Kala Bio Inc. | 0.34% | 298,955 | $1.7M | Add +35.7% |
| VIR Vir Biotechnology Inc. | 0.32% | 250,000 | $1.6M | Add +290.2% |
| RCKT Rocket Pharmaceuticals Inc. | 0.32% | 241,800 | $1.6M | Add +14.4% |
| TSHA Taysha Gene Therapies Inc. | 0.29% | 1,066,309 | $1.5M | Add +500.0% |
| VKTX Viking Therapeutics Inc. | 0.28% | 59,413 | $1.4M | Add +538.9% |
| FULC Fulcrum Therapeutics Inc. | 0.28% | 490,532 | $1.4M | Add +150.0% |
| CRGX Cargo Therapeutics Inc. | 0.28% | 341,515 | $1.4M | New |
| ORKA Oruka Therapeutics Inc. | 0.27% | 132,780 | $1.4M | New |
| SLNO Soleno Therapeutics Inc. | 0.27% | 18,830 | $1.3M | Reduce -48.9% |
| VRNA Verona Pharma Ltd. | 0.25% | 20,000 | $1.3M | Reduce -31.3% |
| CKPT Checkpoint Therapeutics Inc. | 0.24% | 305,800 | $1.2M | New |
| ALDX Aldeyra Therapeutics Inc. | 0.24% | 211,579 | $1.2M | Reduce -67.3% |
| KRRO Korro Bio Inc. | 0.24% | 68,715 | $1.2M | Add +18.5% |
| CTNM Contineum Therapeutics Inc. Class A | 0.23% | 168,765 | $1.2M | Add +105.2% |
| TECX Tectonic Therapeutic Inc. | 0.22% | 62,603 | $1.1M | Add +6.6% |
| VRDN Viridian Therapeutics Inc. | 0.21% | 79,000 | $1.1M | Add +203.8% |
| VTGN Vistagen Therapeutics Inc. | 0.21% | 420,765 | $1.1M | Add +246.4% |
| PFE Pfizer Inc. | 0.21% | 41,050 | $1.0M | Add +17.1% |
| ARES ACQUISITION CORP II | 0.20% | 90,466 | $1.0M | Reduce -34.9% |
| SGRY Surgery Partners Inc. | 0.19% | 40,000 | $950K | New |
| KNSA Kiniksa Pharmaceuticals Inte | 0.18% | 41,412 | $920K | Reduce -75.1% |
| ACLX Arcellx Inc. | 0.18% | 13,962 | $916K | Add +252.4% |
| REGN Regeneron Pharmaceuticals | 0.17% | 1,361 | $863K | No change |
| KVAUF Keen Vision Acquisition Corp. | 0.17% | 75,000 | $842K | No change |
| AGIO Agios Pharmaceuticals Inc. | 0.16% | 27,900 | $817K | New |
| GRCE Grace Therapeutics Inc. | 0.16% | 343,512 | $783K | Reduce -55.6% |
| KZR Kezar Life Sciences Inc. | 0.14% | 147,404 | $719K | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.14% | 56,300 | $717K | Add +336.4% |
| GPCR Structure Therapeutics Inc. | 0.12% | 35,619 | $617K | Add +0.8% |
| BIIB Biogen Inc. | 0.12% | 4,500 | $616K | Add +47.8% |
| ITOS Iteos Therapeutics Inc. | 0.12% | 101,096 | $604K | Reduce -23.2% |
| NTRA Natera Inc. | 0.12% | 4,250 | $601K | New |
| ZYME Zymeworks Inc. | 0.12% | 50,000 | $596K | New |
| LXEO Lexeo Therapeutics Inc. | 0.12% | 170,448 | $591K | Add +0.6% |
| KPRX Kiora Pharmaceuticals Inc. | 0.12% | 194,665 | $586K | Reduce -2.8% |
| SPRO Spero Therapeutics Inc. | 0.11% | 801,277 | $577K | No change |
| BHVN Biohaven Ltd. | 0.11% | 22,641 | $544K | New |
| TARA Protara Therapeutic Inc. | 0.10% | 122,690 | $523K | No change |
| USFR Wisdomtree Floating Rate Tre | 0.10% | 10,000 | $503K | No change |
| ANSC Agriculture & Natural Soluti | 0.10% | 47,062 | $502K | Reduce -41.4% |
| LLY Eli Lilly & Co. | 0.10% | 600 | $496K | Reduce -55.6% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.10% | 1,490 | $494K | New |
| PCVX Vaxcyte Inc. | 0.10% | 12,800 | $483K | New |
| RNXT Renovorx Inc. | 0.09% | 479,883 | $475K | Add +143.3% |
| ALEC Alector Inc. | 0.09% | 380,330 | $468K | Add +3.3% |
| INSM Insmed Inc. | 0.09% | 6,074 | $463K | Reduce -72.4% |
Options reported separately and not counted above: JANX calls ($7.2M), NVS puts ($5.6M), SLNO puts ($3.6M), SMMT calls ($1.9M), SWTX calls ($662K), PHAT calls ($63K).
Other holdings (11): bonds, preferreds, convertibles and warrants · $14.6M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | 5,625,000 | $5.5M | No change |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 4,500,000 | $4.0M | No change |
| BRIDGEBIO PHARMA INC | NOTE 1.750% 3/0 · principal | 2,666,627 | $2.7M | New |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 2,000,000 | $2.3M | No change |
| AAM.WS Aa Mission Acquisition -30 | *W EXP 08/01/203 | 505,099 | $34K | No change |
| ASPCR A Spac III Acquisition Corp. | RIGHT 01/02/2026 | 215,000 | $30K | New |
| JVSAR Jvspac Acquisition Corp.-RTS | RIGHT 11/26/2026 | 30,000 | $8K | No change |
| IROHR Iron Horse Acquisitions Righ | RIGHT 99/99/9999 | 25,000 | $8K | No change |
| EMCRF Embrace Change Acq-Rights | RIGHT 10/25/2026 | 13,144 | $2K | No change |
| UCFIW Iron Horse Acquisition Co.-29 | *W EXP 09/30/203 | 25,000 | $800 | No change |
| EMCWF Embrace Change Acquisitio-26 | *W EXP 10/25/202 | 18,000 | $695 | No change |
Total filed on the 13F, all lines: $519.7M.
Portfolio Sells Q4 2024 → Q1 2025
| ASND Ascendis Pharma A/S | Reduce -98.0% | 0.04% | −2.05 |
| ROIV Roivant Sciences Ltd. | Reduce -0.7% | 6.96% | −1.89 |
| BBIO Bridgebio Pharma Inc. | Reduce -50.0% | 2.32% | −1.64 |
| EDR Endeavor Group Hold Class A | Sold out | 0.00% | −1.40 |
| MLYS Mineralys Therapeutics Inc. | Reduce -68.7% | 0.83% | −1.38 |
| CYTK Cytokinetics Inc. | Reduce -5.7% | 3.11% | −1.04 |
| SNY Sanofi-ADR | Sold out | 0.00% | −1.02 |
| RZLT Rezolute Inc. | Reduce -17.9% | 0.64% | −0.78 |
| KNSA Kiniksa Pharmaceuticals Inte | Reduce -75.1% | 0.18% | −0.52 |
| GRCE Grace Therapeutics Inc. | Reduce -55.6% | 0.16% | −0.46 |
| ALDX Aldeyra Therapeutics Inc. | Reduce -67.3% | 0.24% | −0.45 |
| PLRX Pliant Therapeutics Inc. | Sold out | 0.00% | −0.38 |
| PVLA Palvella Therapeutics Inc. | Sold out | 0.00% | −0.37 |
| AXSM Axsome Therapeutics Inc. | Sold out | 0.00% | −0.35 |
| CDMO Avid Bioservices Inc. | Sold out | 0.00% | −0.32 |
| SLRN Acelyrin Inc. | Sold out | 0.00% | −0.30 |
| PSTX Poseida Therapeutics Inc. | Sold out | 0.00% | −0.27 |
| RPRX Royalty Pharma PLC Class A | Sold out | 0.00% | −0.27 |
| ACOG Alpha Cognition Inc. | Sold out | 0.00% | −0.26 |
| INSM Insmed Inc. | Reduce -72.4% | 0.09% | −0.23 |
| IBIO Ibio Inc. | Sold out | 0.00% | −0.22 |
| BEAM Beam Therapeutics Inc. | Sold out | 0.00% | −0.20 |
| DHR Danaher Corp. | Sold out | 0.00% | −0.20 |
| MRUS Merus NV | Reduce -17.8% | 0.56% | −0.17 |
| GERN Geron Corp. | Reduce -21.2% | 0.08% | −0.17 |
| CAPR Capricor Therapeutics Inc. | Sold out | 0.00% | −0.17 |
| MLTX Moonlake Immunotherapeutics | Reduce -68.9% | 0.04% | −0.16 |
| DNLI Denali Therapeutics Inc. | Reduce -69.0% | 0.04% | −0.16 |
| NMRA Neumora Therapeutics Inc. | Reduce -62.0% | 0.01% | −0.15 |
| OABI Omniab Inc. | Reduce -54.7% | 0.06% | −0.15 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −0.15 |
| INDV Indivior Ltd. | Sold out | 0.00% | −0.14 |
| ARES ACQUISITION CORP II | Reduce -34.9% | 0.20% | −0.13 |
| LLY Eli Lilly & Co. | Reduce -55.6% | 0.10% | −0.12 |
| ONC Beone Medicines Ltd.-ADR | Sold out | 0.00% | −0.12 |
| SDGR Schrodinger Inc. | Sold out | 0.00% | −0.10 |
| VYGR Voyager Therapeutics Inc. | Reduce -40.4% | 0.05% | −0.10 |
| SLDB Solid Biosciences Inc. | Reduce -76.8% | 0.03% | −0.10 |
| DAWN Day One Biopharmaceuticals I | Reduce -47.1% | 0.04% | −0.10 |
| OGN Organon & Co. | Reduce -75.1% | 0.03% | −0.10 |
| ITOS Iteos Therapeutics Inc. | Reduce -23.2% | 0.12% | −0.10 |
| CMRX Chimerix Inc. | Sold out | 0.00% | −0.09 |
| ABSI Absci Corp. | Sold out | 0.00% | −0.09 |
| SLNO Soleno Therapeutics Inc. | Reduce -48.9% | 0.27% | −0.09 |
| ANSC Agriculture & Natural Soluti | Reduce -41.4% | 0.10% | −0.08 |
| MRNA Moderna Inc. | Sold out | 0.00% | −0.08 |
| AVIR Atea Pharmaceuticals Inc. | Sold out | 0.00% | −0.08 |
| ANAB Anaptysbio Inc. | Sold out | 0.00% | −0.08 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −0.07 |
| ALKS Alkermes PLC | Sold out | 0.00% | −0.06 |
Portfolio Buys Q4 2024 → Q1 2025
| KROS Keros Therapeutics Inc. | Add +6294.5% | 3.00% | +2.92 |
| SWTX Springworks Therapeutics Inc. | New | 1.82% | +1.82 |
| SHY iShares 1-3 Year Treasury Bo | New | 1.69% | +1.69 |
| ITCI Intra-Cellular Therapies Inc. | New | 1.25% | +1.25 |
| SAGE Sage Therapeutics Inc. | Add +3767.2% | 1.17% | +1.15 |
| RAPT THERAPEUTICS INC | Add +408.4% | 1.44% | +1.05 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 1.03% | +1.03 |
| TEVA Teva Pharmaceutical-SP ADR | Add +257.1% | 1.59% | +0.91 |
| SEPN Septerna Inc. | New | 0.83% | +0.83 |
| SRRK Scholar Rock Holding Corp. | Add +705.3% | 1.00% | +0.82 |
| BIOA Bioage Labs Inc. | Add +689.3% | 0.72% | +0.57 |
| SRPT Sarepta Therapeutics Inc. | Add +207.3% | 1.55% | +0.52 |
| ATXS Astria Therapeutics Inc. | Add +605.3% | 0.68% | +0.51 |
| AKRO Akero Therapeutics Inc. | Add +364.8% | 0.57% | +0.48 |
| JANX Janux Therapeutics Inc. | Add +388.0% | 0.82% | +0.46 |
| ARDX Ardelyx Inc. | Add +1481.3% | 0.48% | +0.44 |
| DVAX Dynavax Technologies Corp. | New | 0.44% | +0.44 |
| ARVN Arvinas Inc. | New | 0.44% | +0.44 |
| XENE Xenon Pharmaceuticals Inc. | Add +152.3% | 0.85% | +0.43 |
| APGE Apogee Therapeutics Inc. | Add +154.0% | 0.78% | +0.38 |
| ABVX Abivax SA-ADR | Add +46.0% | 2.73% | +0.37 |
| ETNB 89BIO Inc. | Add +56.1% | 1.16% | +0.30 |
| CRGX Cargo Therapeutics Inc. | New | 0.28% | +0.28 |
| ORKA Oruka Therapeutics Inc. | New | 0.27% | +0.27 |
| CKPT Checkpoint Therapeutics Inc. | New | 0.24% | +0.24 |
| TSHA Taysha Gene Therapies Inc. | Add +500.0% | 0.29% | +0.23 |
| VIR Vir Biotechnology Inc. | Add +290.2% | 0.32% | +0.22 |
| RGNX Regenxbio Inc. | Add +105.9% | 0.50% | +0.22 |
| ABUS Arbutus Biopharma Corp. | Add +20.9% | 1.30% | +0.22 |
| VKTX Viking Therapeutics Inc. | Add +538.9% | 0.28% | +0.20 |
| AEROVATE THERAPEUTICS INC | Add +57.5% | 0.73% | +0.20 |
| SGRY Surgery Partners Inc. | New | 0.19% | +0.19 |
| AGIO Agios Pharmaceuticals Inc. | New | 0.16% | +0.16 |
| BBOT Bridgebio Oncology Therapeut | Add +16.2% | 1.05% | +0.15 |
| CGON CG Oncology Inc. | Add +39.6% | 1.46% | +0.14 |
| VTGN Vistagen Therapeutics Inc. | Add +246.4% | 0.21% | +0.13 |
| NTRA Natera Inc. | New | 0.12% | +0.12 |
| ZYME Zymeworks Inc. | New | 0.12% | +0.12 |
| ACLX Arcellx Inc. | Add +252.4% | 0.18% | +0.12 |
| BHVN Biohaven Ltd. | New | 0.11% | +0.11 |
| VRDN Viridian Therapeutics Inc. | Add +203.8% | 0.21% | +0.10 |
| SVRA Savara Inc. | Add +37.6% | 0.75% | +0.10 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 0.10% | +0.10 |
| PCVX Vaxcyte Inc. | New | 0.10% | +0.10 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +336.4% | 0.14% | +0.09 |
| BNTX Biontech SE-ADR | New | 0.09% | +0.09 |
| EWTX Edgewise Therapeutics Inc. | New | 0.09% | +0.09 |
| FULC Fulcrum Therapeutics Inc. | Add +150.0% | 0.28% | +0.08 |
| ARGX Argenx SE - ADR | New | 0.07% | +0.07 |
| THRD Third Harmonic Bio Inc. | New | 0.07% | +0.07 |
Options Activity Q4 2024 → Q1 2025
| JANX Janux Therapeutics Inc. | call | New | 264,900 | $7.2M |
| NVS Novartis AG-Sponsored ADR | put | New | 50,000 | $5.6M |
| PTGX Protagonist Therapeutics Inc. | call | Sold out | 132,000 | $5.1Mbefore exit |
| XBI SS SPDR S&P Biotech ETF | call | Sold out | 50,000 | $4.5Mbefore exit |
| SLNO Soleno Therapeutics Inc. | put | New | 50,000 | $3.6M |
| SMMT Summit Therapeutics Inc. | call | New | 100,000 | $1.9M |
| JNJ Johnson & Johnson | call | Sold out | 10,000 | $1.4Mbefore exit |
| CAPR Capricor Therapeutics Inc. | call | Sold out | 95,000 | $1.3Mbefore exit |
| CYTK Cytokinetics Inc. | call | Sold out | 15,100 | $710Kbefore exit |
| SWTX Springworks Therapeutics Inc. | call | New | 15,000 | $662K |
| AKRO Akero Therapeutics Inc. | call | Sold out | 22,500 | $626Kbefore exit |
| APLT Applied Therapeutics Inc. | call | Sold out | 530,324 | $454Kbefore exit |
| BMRN Biomarin Pharmaceutical Inc. | call | Sold out | 5,000 | $329Kbefore exit |
| TARS Tarsus Pharmaceuticals Inc. | call | Sold out | 5,000 | $277Kbefore exit |
| RGNX Regenxbio Inc. | call | Sold out | 17,800 | $138Kbefore exit |
| CRVS Corvus Pharmaceuticals Inc. | put | Sold out | 15,000 | $80Kbefore exit |
| CRVS Corvus Pharmaceuticals Inc. | call | Sold out | 10,000 | $54Kbefore exit |
| AMLX Amylyx Pharmaceuticals Inc. | call | Sold out | 10,000 | $38Kbefore exit |
| GOSS Gossamer Bio Inc. | call | Sold out | 19,898 | $18Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q4 2024 → Q1 2025
| GOSSAMER BIO INC (GOSS 5 06/01/27) | NOTE 5.000% 6/0 · principal | Sold out | 8,000,000 | $4.4Mbefore exit |
| BRIDGEBIO PHARMA INC | NOTE 1.750% 3/0 · principal | New | 2,666,627 | $2.7M |
| ASPCR A Spac III Acquisition Corp. | RIGHT 01/02/2026 | New | 215,000 | $30K |
| GLSTR Global Star Acquisition-RTS | RIGHT 99/99/9999 | Sold out | 88,560 | $13Kbefore exit |
| GLSTW Global Star Acquisition-27 A | *W EXP 07/15/202 | Sold out | 120,000 | $4Kbefore exit |
| FTIIW Futuretech II Acq -CW27 | *W EXP 08/18/202 | Sold out | 30,000 | $462before exit |
| AIMWF Aimfinity Investment-CW27 | *W EXP 99/99/999 | Sold out | 18,000 | $126before exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |